Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers

被引:65
作者
Kohmoto, M
Enomoto, K
Tamori, A
Habu, D
Takeda, T
Kawada, N
Sakaguchi, K
Seki, S
Shiomi, S
Nishiguchi, S
机构
[1] Osaka City Univ, Sch Med, Dept Hepatol, Abeno Ku, Osaka 5458585, Japan
[2] Osaka City Univ, Sch Med, Dept Nucl Med, Abeno Ku, Osaka, Japan
关键词
HBsAg; HBV; HBV mutants; hepatitis B virus; YMDD variants; lamivudine therapy;
D O I
10.1002/jmv.20262
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The usefulness of fully automated chemiluminescent microparticle immunoassay (Architect HBsAg QT) for monitoring serum levels of hepatitis B virus (HBV) during antiviral therapy remains unclear. Using this assay, hepatitis B surface antigen (HBsAg) was measured in 20 patients with chronic hepatitis B before and during lamivudine treatment. At the start of therapy, 12 patients had detectable hepatitis B e antigen (HBeAg) and 8 did not. The median serum HBV DNA level and HBsAg concentration (25th-75th centile) were 7.2 (6.1-7.8) log genome equivalents/ml and 3,932 (1,585-12,330) IU/ml, respectively. The HBsAg concentration was significantly higher in HBeAg positive than in HBeAg negative patients (P = 0.031). There was a significant correlation between the HBsAg concentration and HBV DNA level (r = 0.490, P = 0.027). The HBsAg concentration negatively correlated with patient age (r = -0.395, P = 0.085). After the start of lamivudine therapy, HBV DNA levels fell rapidly in all patients. Serum HBsAg concentrations also fell in most patients, but to a lesser extent. When drug-resistant variants emerged, serum HBsAg usually increased before biochemical breakthrough. Although HBV DNA was elevated persistently after the emergence of drug-resistant variants, the increase in HBsAg was transient. In some patients, the increase in HBsAg preceded the increase in HBV DNA. Monitoring of serum HBsAg concentrations with the use of Architect HBsAg QT, in addition to measurement of HBV DNA levels, is helpful for evaluating the response to lamivudine treatment and for the early detection of drug-resistant strains. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:235 / 239
页数:5
相关论文
共 17 条
[1]  
Coleman PF, 1999, J MED VIROL, V59, P19, DOI 10.1002/(SICI)1096-9071(199909)59:1<19::AID-JMV4>3.0.CO
[2]  
2-B
[3]   Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay [J].
Deguchi, M ;
Yamashita, N ;
Kagita, M ;
Asari, S ;
Iwatani, Y ;
Tsuchida, T ;
Iinuma, K ;
Mushahwar, IK .
JOURNAL OF VIROLOGICAL METHODS, 2004, 115 (02) :217-222
[4]   Lamivudine as initial treatment for chronic hepatitis B in the United States [J].
Dienstag, JL ;
Schiff, ER ;
Wright, TL ;
Perrillo, RP ;
Hann, HWL ;
Goodman, Z ;
Crowther, L ;
Condreay, LD ;
Woessner, M ;
Rubin, M ;
Brown, NA .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (17) :1256-1263
[5]  
Fan TJ, 2001, ACTA BIOCH BIOPH SIN, V33, P7
[6]   Clinical evaluation and applications of the Amplicor HBV Monitor™ test, a quantitative HBV DNA PCR assay [J].
Gerken, G ;
Gomes, J ;
Lampertico, P ;
Colombo, M ;
Rothaar, T ;
Trippler, M ;
Colucci, G .
JOURNAL OF VIROLOGICAL METHODS, 1998, 74 (02) :155-165
[7]  
Ghany MG, 2000, HEPATOLOGY, V32, p376A, DOI 10.1053/jhep.2000.17912
[8]   Transcription-mediated amplification is more useful in the follow-up of patients with chronic hepatitis B treated with lamivudine [J].
Ide, T ;
Kumashiro, R ;
Hino, T ;
Murashima, S ;
Ogata, K ;
Koga, Y ;
Sata, M .
HEPATOLOGY RESEARCH, 2001, 21 (01) :76-84
[9]   Limitations and improvements of the quantiplex branched-DNA assay in Hepatitis B virus-infected patients receiving lamivudine [J].
Jen, CM ;
Young, KC ;
Cheng, PN ;
Kao, AW ;
Chang, TT .
JOURNAL OF VIROLOGICAL METHODS, 2001, 96 (02) :203-210
[10]   Quantitative detection of hepatitis B virus by transcription-mediated amplification and hybridization protection assay [J].
Kamisango, K ;
Kamogawa, C ;
Sumi, M ;
Goto, S ;
Hirao, A ;
Gonzales, F ;
Yasuda, K ;
Iino, S .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (02) :310-314